CHI3L1 and Tako-tsubo cardiomyopathy: In this study, we demonstrated that YKL-40 can represent an innovative biomarker with potential clinical implications for ASC patients management: YKL-40 high serum level identified ASC patients with worse survival and can be used as a prognostic biomarker for patient overall survival, while YKL-40 increased protein expression in the peritumor immune cells characterized ASC patient non-responsive to CRT and can serve as a predictive biomarker.